"SK-MEL-5人皮膚黑色素瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

細(xì)胞系的選擇需要考慮到細(xì)胞系的功能特點、生長速率、鋪板效率、生長條件和生長特征、克隆效率、培養(yǎng)方式等因素，如果您想高產(chǎn)量表達(dá)重組蛋白，您可以選擇可以懸浮生長的快速生長細(xì)胞系。細(xì)胞培養(yǎng)的操作步驟主要包括傳代、換液、凍存和復(fù)蘇。這些步驟確保了細(xì)胞能夠在實驗室環(huán)境中長期存活并繼續(xù)增殖。傳代是將細(xì)胞從一個容器轉(zhuǎn)移到另一個容器的過程，以擴(kuò)大細(xì)胞數(shù)量；換液是為了清除代謝廢物并補(bǔ)充新鮮培養(yǎng)基；凍存則是為了長期保存細(xì)胞，而復(fù)蘇則是重新激活冷凍保存的細(xì)胞使其恢復(fù)正常生長。

換液周期：每周2-3次

KGN Cells;背景說明：該細(xì)胞株是顆粒細(xì)胞瘤。細(xì)胞在加入人體絨膜促性腺激素后可能產(chǎn)生孕酮。細(xì)胞生長緩慢。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：SO-RB50細(xì)胞、HS688AT細(xì)胞、SKCO1細(xì)胞

FU-OV-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH526細(xì)胞、MDA-MB-231-GFP細(xì)胞、U-CH1細(xì)胞

HS-294T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：混合星狀和多邊形;相關(guān)產(chǎn)品有：HF-91細(xì)胞、Hep 2細(xì)胞、LIXC002細(xì)胞

SK-MEL-5人皮膚黑色素瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：詳見相關(guān)文獻(xiàn)介紹

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

細(xì)胞根據(jù)其形態(tài)和功能可以分為多種類型，其中上皮細(xì)胞、成纖維細(xì)胞和淋巴母細(xì)胞是常見的三種類型。成纖維細(xì)胞，或稱纖維母細(xì)胞，是一種存在于蜂窩組織或纖維結(jié)締組織中的梭形細(xì)胞，能夠分泌構(gòu)成細(xì)胞外基質(zhì)(ECM)的結(jié)構(gòu)蛋白。這類細(xì)胞最初由德國病理學(xué)家魯?shù)婪颉し茽柦B與法國解剖學(xué)家馬蒂亞斯·杜瓦爾于19世紀(jì)中葉描述。成纖維細(xì)胞特異性標(biāo)志物包括FAP(成纖維細(xì)胞激活蛋白)、α-SMA(α-平滑肌肌動蛋白)、骨膜蛋白、PDGFRα(血小板衍生生長因子受體α)、膠原蛋白、波形蛋白、纖連蛋白和胸腺細(xì)胞抗原1等。成纖維細(xì)胞在形態(tài)上是扁平的紡錘形細(xì)胞，缺乏基底膜，細(xì)胞核呈圓形拉長，被巨大的內(nèi)質(zhì)網(wǎng)包圍。在培養(yǎng)中，它們表現(xiàn)出不同的形態(tài)學(xué)和生化特征，這取決于其起源位置、分化狀態(tài)和培養(yǎng)條件。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

SK-MEL-5人皮膚黑色素瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來源：人源、鼠源等其它物種來源

NCIH2073 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代 ;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：BCECs細(xì)胞、L23/P細(xì)胞、ECC1細(xì)胞

2780 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：aTC1 Clone 6細(xì)胞、T-47D細(xì)胞、HCC-1428細(xì)胞

OP-9 Cells;背景說明：骨髓基質(zhì)；C５７BL/６ x C３H;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MADB-106細(xì)胞、RERF-LCMS細(xì)胞、Y3-Ag1.2.3細(xì)胞

Bovine Turbinate Cells;背景說明：鼻甲；自發(fā)永生；Holstein;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MARC-145細(xì)胞、TCC-PAN2細(xì)胞、RPMI-1846細(xì)胞

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：上皮細(xì)胞樣

細(xì)胞凍存復(fù)蘇材料與方法步驟：常用的細(xì)胞冷凍貯存器為貯存器，規(guī)格有３５L和５０L兩種。使用時要注意以下幾點：(１)一般兩周需充一次，至少一個月充一次。溫度達(dá)-１９６℃，使用時注意勿讓濺到皮膚上，以免引起凍傷。(２)容器為雙層結(jié)構(gòu)，中間為真空層，瓶口有雙層焊接處，應(yīng)防止焊接部裂開。(３)在裝入時，要注意緩慢小心，并用厚紙卷筒或制漏斗作引導(dǎo)，使直達(dá)瓶底，如有專用灌注裝置則更HAO。若為初次使用，加時更要緩慢，以免溫度驟降而使容器損壞。細(xì)胞凍存時常備的材料有：０.２５%胰蛋白酶，含１０%～２０%的血清培養(yǎng)，DMSO(分析純)或無色新鮮甘油(１２１°C蒸氣GAO壓消毒)，２mL安瓿(或?qū)Ｓ眉?xì)胞凍存管)、吸管、離心管、噴燈、紗布袋(或凍存管架)等。主要操作步驟為：(１)選擇處于對數(shù)生長期的細(xì)胞，在凍存前一天ZuiHAO換。將多個培養(yǎng)瓶中的細(xì)胞培養(yǎng) 去掉，用０.２５%胰蛋白酶消化。適時去掉胰蛋白酶，加入少量新培養(yǎng)。用吸管吸取培養(yǎng)反復(fù)吹打瓶壁上的細(xì)胞，使其成為均勻分散的細(xì)胞懸。懸浮生產(chǎn)細(xì)胞則不要消化處理。然后將細(xì)胞收集于離心管中離心(１０００r/min，１０分鐘)。(２)去上清，加入含２０%小牛血清的完全培養(yǎng)基，于４℃預(yù)冷１５分鐘后，逐滴加入已無菌的DMSO或甘油，用吸管輕輕吹打使細(xì)胞均勻，細(xì)胞濃度為３×１０６～１×１０７/mL之間。(３)將上述細(xì)胞分裝于安瓿或?qū)Ｓ美鋬鏊芰瞎苤?，安瓿裝１～１.５mL在火焰噴燈上封口，封口處要完全封閉，圓滑無勾。冷凍管要將蓋子蓋緊，并標(biāo)記HAO細(xì)胞名稱和凍存日期，同時作HAO登記(日期、細(xì)胞種類及代次、凍存支數(shù))。(４)將裝HAO細(xì)胞的安瓿或凍存管裝入沙布袋內(nèi);置于容器頸口處存放過夜，次日轉(zhuǎn)入中。采用控制降溫速度的方法也可采用下列步驟：先將安瓿置入４℃冰箱中２～３小時，再移至冰箱冷凍室內(nèi)３～４小時，再吊入容器頸氣態(tài)部分存放２小時，Zui后沉入中。細(xì)胞凍存在中可以長期保存，但為妥善起見，凍存半年后，ZuiHAO取出一只安瓿細(xì)胞復(fù)蘇培養(yǎng)，觀察生長情況，然后再繼續(xù)凍存。

RBMEC Cells;背景說明：腦微血管；內(nèi)皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：mRTEC細(xì)胞、Hs 729細(xì)胞、Ramos(RA1)細(xì)胞

COLO 320 DM Cells;背景說明：該細(xì)胞可產(chǎn)生５-羥色胺、去甲、、ACTH和甲狀旁腺素。角蛋白、波形蛋白弱陽性。培養(yǎng)條件： RPMI １６４０  １０%FBS;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮+貼壁;形態(tài)特性：淋巴細(xì)胞;相關(guān)產(chǎn)品有：HT 1197.T細(xì)胞、WPMY1細(xì)胞、SK-MEL-2-LUC細(xì)胞

MNNG-HOS (TE 85, clone F-5) Cells;背景說明：骨肉瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SHP-77細(xì)胞、JF305細(xì)胞、SKMEL28細(xì)胞

A-172 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK Mel 2細(xì)胞、HPAF-2細(xì)胞、KALS-1細(xì)胞

HM Cells;背景說明：小神經(jīng)膠質(zhì) Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCC1143細(xì)胞、P388D1細(xì)胞、SK-Mel 1細(xì)胞

Ly3 Cells;背景說明：彌漫大B淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H295R細(xì)胞、MDA-MB-330細(xì)胞、LLC-WRC 256細(xì)胞

Ly19 Cells;背景說明：彌漫大B淋巴瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CRFK細(xì)胞、SuperTube細(xì)胞、NB9細(xì)胞

NK-92MI Cells;背景說明：NK細(xì)胞；淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SLMT1細(xì)胞、SUPB-15細(xì)胞、NCI-SNU-407細(xì)胞

SCI1 Cells;背景說明：胚胎；自發(fā)永生;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HC11 Mammary Epithelium細(xì)胞、SK-NSH細(xì)胞、PIGI細(xì)胞

A2780/CP Cells;背景說明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HGC-27細(xì)胞、Hs-746T細(xì)胞、SNU-601細(xì)胞

Rat Skin 1 Cells;背景說明：該細(xì)胞系來源于一大鼠的皮膚組織。２００７年由中國科學(xué)院昆明細(xì)胞庫建立。;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：UCLA SO M21細(xì)胞、B16BL-6細(xì)胞、CAL39細(xì)胞

BetaTC6 Cells;背景說明：這株細(xì)胞來源于轉(zhuǎn)基因小鼠中生長的一個胰腫瘤(胰島素瘤)。這種小鼠攜帶了大鼠胰島素II基因啟動子調(diào)控的SV４０早期基因的假基因結(jié)構(gòu)。細(xì)胞包含豐富的胰島素和小量的胰高血糖素及生長抑素。響應(yīng)葡萄糖而分泌胰島素;傳代方法：１：２-１：４傳代，每２-３天換液一次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：NIH-OVCAR-3細(xì)胞、Hs895.T細(xì)胞、A-172細(xì)胞

HGC-27 Cells;背景說明：未分化胃癌，能分泌粘液素。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：FLS細(xì)胞、H510細(xì)胞、Roswell Park Memorial Institute 7951細(xì)胞

GLAG-66 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Molm 13細(xì)胞、RPMI7666細(xì)胞、SV-HUC-1細(xì)胞

BCAP37 Cells;背景說明：源自一位４８歲女性乳癌患者。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HSCT6細(xì)胞、HSC-3細(xì)胞、GM00637細(xì)胞

SVOG Cells;背景說明：卵巢；顆粒 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Panc-1-P細(xì)胞、HCC94細(xì)胞、B10BR細(xì)胞

DU_145 Cells;背景說明：DU １４５ 是從一位有３年淋巴細(xì)胞白血病史的前列腺癌患者的腦部轉(zhuǎn)移灶中建立的。該細(xì)胞系未檢測到激素敏感性，酸性酶陽性，單個的細(xì)胞可在軟瓊脂中形成集落。對此細(xì)胞和原始腫瘤的亞顯微結(jié)構(gòu)分析可見微絨毛、微絲、細(xì)胞橋粒、線粒體、發(fā)達(dá)的高爾基體和異質(zhì)溶酶體。該細(xì)胞不表達(dá)前列腺抗原。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：ETCC-007細(xì)胞、FT-293細(xì)胞、RCC 7860細(xì)胞

ABC08 Cells(提供STR鑒定圖譜)

Abcam Raji MAEA KO Cells(提供STR鑒定圖譜)

Bayer/BCIRL-SfNS-0624-C5-TR Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRR636 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YTA118 Cells(提供STR鑒定圖譜)

CHA-hES40 Cells(提供STR鑒定圖譜)

DA01719 Cells(提供STR鑒定圖譜)

F2408-No.3 Cells(提供STR鑒定圖譜)

GM07523 Cells(提供STR鑒定圖譜)

Hs839T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：U-87MG ATCC細(xì)胞、PANC0203細(xì)胞、SK-Hep1細(xì)胞

SK-MEL-5人皮膚黑色素瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

Mino Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：EoL-1-cell細(xì)胞、LM6細(xì)胞、RPMI.8226細(xì)胞

Institute for Medical Research-90 Cells;背景說明：W.W. Nichols及其同事從一位１６周女嬰的肺中取材，建立了人二倍體成纖維細(xì)胞株IMR-９０。分裂潛能，病毒感受性和其它性質(zhì)都得到了充分研究，因而這株細(xì)胞可以作為WI-３８或其它標(biāo)準(zhǔn)人肺細(xì)胞株的替代株。有報道稱這株細(xì)胞在表現(xiàn)出衰老前可倍增５８次。;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CACO2細(xì)胞、NCIH2009細(xì)胞、NCI-H322T細(xì)胞

SK-RC-20 Cells;背景說明：腎癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CT 26細(xì)胞、L 1210細(xì)胞、TE 32.T細(xì)胞

MF2059 Cells;背景說明：皮膚；T淋巴細(xì)胞瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WM266mel細(xì)胞、HBL 100細(xì)胞、SU.86細(xì)胞

RKO_AS45 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCL-H548細(xì)胞、X63-Ag8.653細(xì)胞、Saos2細(xì)胞

B/CMBA.Ov Cells(提供STR鑒定圖譜)

NCIH2110 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代，每周換液２-３次;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：CL1.0細(xì)胞、SK-N-BE(1)細(xì)胞、LA 4細(xì)胞

U-373MG ATCC Cells;背景說明：膠質(zhì)瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：IPLB-Sf21-AE細(xì)胞、A2780-CP細(xì)胞、HK-2 [Human kidney]細(xì)胞

UACC812 Cells;背景說明：該細(xì)胞是由Liebovitz A等于１９８６年從一名４３歲的白人女性乳腺導(dǎo)管癌患者的乳腺切除腫瘤組織中分離建立的；手術(shù)前該病人曾接受過廣泛的化療。該細(xì)胞HER-２/neu癌基因序列有１５倍的擴(kuò)增；雌激素受體ER、孕激素受體PR和糖蛋白P陰性。;傳代方法：１：３傳代；５-７天１次?！?生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SNU-719細(xì)胞、HAEC細(xì)胞、SW1990細(xì)胞

L929 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H1792細(xì)胞、HuCC-T1細(xì)胞、293 EBNA細(xì)胞

OCI-LY-1 Cells;背景說明：彌漫大B淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hs 445細(xì)胞、L6細(xì)胞、SMMC7721細(xì)胞

Potorous tridactylus Kidney 1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Caco-2BBe細(xì)胞、Eca-109細(xì)胞、H157細(xì)胞

IEC 18 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：H865細(xì)胞、alpha-TC1-6細(xì)胞、CL-40細(xì)胞

H-1373 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：４傳代；２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HCO細(xì)胞、CHP 212細(xì)胞、MCFs細(xì)胞

GM50059 Cells(提供STR鑒定圖譜)

HAP1 PHF3 (-) 3 Cells(提供STR鑒定圖譜)

Kupffer Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hs-729-T細(xì)胞、HN 4細(xì)胞、SUM 190PT細(xì)胞

H-548 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HHL-5細(xì)胞、BMSC/hBMSCs細(xì)胞、HR8348細(xì)胞

A2780/CP Cells;背景說明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HGC-27細(xì)胞、Hs-746T細(xì)胞、SNU-601細(xì)胞

H661 Cells;背景說明：該細(xì)胞１９８２年建系，源自一位患有大細(xì)胞肺癌的男性的胸腔積液。該細(xì)胞角蛋白、波形蛋白陽性。;傳代方法：１：３—１：５傳代，每周換液２—３次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：ABC1細(xì)胞、BHK21細(xì)胞、TSUpr1細(xì)胞

Hu-P-T4 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：COV362細(xì)胞、697細(xì)胞、Menschliche Und Tierische Zellkulture-3細(xì)胞

HCA 7 Cells;背景說明：結(jié)腸腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-292細(xì)胞、GC1-SPG細(xì)胞、AR4-IP細(xì)胞

H-2126 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，每周２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：A253細(xì)胞、VCaP細(xì)胞、Be Wo細(xì)胞

Panc_05_04 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：JIMT1細(xì)胞、H2172細(xì)胞、McARH7777細(xì)胞

HSC-7 Cells(提供STR鑒定圖譜)

KOLF2.1J TARDBP Q331K SNV/SNV Cells(提供STR鑒定圖譜)

Monca Cells(提供STR鑒定圖譜)

NYSCF-10005-1071-1071-Skin-mR-iPS Cells(提供STR鑒定圖譜)

RG-399 Cells(提供STR鑒定圖譜)

Ubigene HCT 116 IFIT1 KO Cells(提供STR鑒定圖譜)

WA01 TH-TdTomato Cells(提供STR鑒定圖譜)

HE46 Cells(提供STR鑒定圖譜)

GM-215 Cells;背景說明：肺；自發(fā)永生；雄性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H2286細(xì)胞、KP-N-YN細(xì)胞、MonoMac 6細(xì)胞

HEB Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KMS26細(xì)胞、H-847細(xì)胞、EB1細(xì)胞

GM04678 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周２-３次。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：P388細(xì)胞、L cells (TK-)細(xì)胞、GCT細(xì)胞

HCC202 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：NKM1細(xì)胞、WEHI 164 TC細(xì)胞、SUDHL16細(xì)胞

A-204 Cells;背景說明：在裸鼠中成瘤。;傳代方法：１：６-１：１０傳代；每周２-３次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：COLO 205細(xì)胞、P31/FUJ細(xì)胞、NCI H345細(xì)胞

A-204 Cells;背景說明：在裸鼠中成瘤。;傳代方法：１：６-１：１０傳代；每周２-３次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：COLO 205細(xì)胞、P31/FUJ細(xì)胞、NCI H345細(xì)胞

Hs68 Cells;背景說明：該細(xì)胞１９６９年由Owens RB建立。;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DMS 114細(xì)胞、OCI-LY-1細(xì)胞、M21細(xì)胞

SW620 Cells;背景說明：SW６２０是從一個５１歲男性白人組織中分離得到。由A.Leibovitz等從一個淋巴結(jié)建株。細(xì)胞系主要由無絨毛的小園球細(xì)胞和雙極細(xì)胞組成。它僅合成少量癌胚抗原（CEA）且在裸鼠中有高度的致瘤性;傳代方法：１：３傳代，２-３天換液一次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Granta 519細(xì)胞、MD Anderson-Metastatic Breast-436細(xì)胞、Vero-76細(xì)胞

MHCC 97-H Cells;背景說明：來源于中山醫(yī)院，用人肝癌細(xì)胞株MHCC９７-H接種裸鼠，進(jìn)行３次肺轉(zhuǎn)移篩選，取肺轉(zhuǎn)移瘤建成皮下接種后高度自發(fā)性肺轉(zhuǎn)移的肝癌細(xì)胞系;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：NIT-1細(xì)胞、SW-626細(xì)胞、16HBEo-細(xì)胞

SUM-149PT Cells;背景說明：乳腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：AU 565細(xì)胞、LIM 1215細(xì)胞、HEYA8細(xì)胞

A 375 Cells;背景說明：A３７５源自一位５４歲女性，是Giard DJ等人建立的一系列細(xì)胞株中的一株。該細(xì)胞可在免疫抑制小鼠上成瘤，在瓊脂上形成克隆。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：Hs 746T細(xì)胞、MCF-7/ADR細(xì)胞、451Lu細(xì)胞

A101D Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：６傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：SNU-C2B細(xì)胞、NCI-A549細(xì)胞、B6Tert-1細(xì)胞

ME1 Cells;背景說明：急性髓系白血病；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TE9細(xì)胞、Tb 1 Lu (NBL-12)細(xì)胞、NCI-H2228細(xì)胞

Kit-225-K6 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OVCA-420細(xì)胞、H4IIEC3細(xì)胞、ABE-8.1/2細(xì)胞

PANC-04-03 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MPC-83細(xì)胞、ADR-RES細(xì)胞、H-II-E-C3細(xì)胞

SU-DHL-2 Cells(提供STR鑒定圖譜)

COLO-320-HSR Cells;背景說明：該細(xì)胞１９８４年建系，源自一位３３歲患有大腸腺癌男性經(jīng)５-fu治療后的腹水。;傳代方法：１：２傳代。３天內(nèi)可長滿。;生長特性：半貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OVCA 433細(xì)胞、TERT-RPE1細(xì)胞、RPTEC/TERT1細(xì)胞

MFC Cells;背景說明：胃癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MC3T3-L1細(xì)胞、C-Li-7細(xì)胞、Stanford University-Diffuse Histiocytic Lymphoma-2細(xì)胞

P3JHR1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每２-３天換液;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：CEMC7細(xì)胞、ECC-10細(xì)胞、JB6Cl30細(xì)胞

SCL II Cells;背景說明：皮膚鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：IBRS-2細(xì)胞、HO-8910細(xì)胞、J774.A1細(xì)胞

NS-1 Cells;背景說明：這是P３X６３Ag８(ATCCTIB-９)的一個不分泌克隆。Kappa鏈合成了但不分泌。能抗０.１mM８-氮雜鳥嘌呤但不能在HAT培養(yǎng)基中生長。據(jù)報道它是由于缺失了３-酮類固醇還原酶活性的膽固醇營養(yǎng)缺陷型。檢測表明肢骨發(fā)育畸形病毒(鼠痘)陰性。;傳代方法：１：２傳代，３天內(nèi)可長滿。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：MADB 106細(xì)胞、MLOY4細(xì)胞、KYSE-140細(xì)胞

WiDrTC Cells;背景說明：結(jié)腸癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SNU-251細(xì)胞、H-1954細(xì)胞、CHO-K1細(xì)胞

SK-MEL-5人皮膚黑色素瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

KYSE-270 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：５傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MCA 38細(xì)胞、NCI-H2108細(xì)胞、GM02132C細(xì)胞

SK-N-BE(2)-C Cells;背景說明：神經(jīng)母細(xì)胞瘤；骨髓轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HOS (TE85)細(xì)胞、HCC 2185細(xì)胞、PL9細(xì)胞

H28 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代，每周換液２-３次;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H1618細(xì)胞、HOK細(xì)胞、V79-GalK1細(xì)胞

RPMI1846 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KYSE50細(xì)胞、WEHI3細(xì)胞、Panc5.04細(xì)胞

AE 1201 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Ly10細(xì)胞、Caco2-BBE細(xì)胞、LK-2細(xì)胞

MRMT-1 Cells;背景說明：乳腺癌；SD;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HOEC細(xì)胞、AK細(xì)胞、Human fetal lung fibroblast 1細(xì)胞

GM02131 Cells;背景說明：B淋巴細(xì)胞；EBV轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：GOS3細(xì)胞、LPC-H12細(xì)胞、H1355細(xì)胞

Panc08.13 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：OVCAR-420細(xì)胞、NTERA-2cl.D1細(xì)胞、Pa16C細(xì)胞

BayGenomics ES cell line RRK206 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XL797 Cells(提供STR鑒定圖譜)

Gibco CF6-Neo Mouse Embryonic Fibroblasts, Irradiated Cells(提供STR鑒定圖譜)

OHP138.H8.1 Cells(提供STR鑒定圖譜)

Zfp57+/- clone 6911 Cells(提供STR鑒定圖譜)

MCW043i-U2326 Cells(提供STR鑒定圖譜)

" "PubMed=313568; DOI=10.1073/pnas.76.6.2898; PMCID=PMC383717

Carey T.E., Lloyd K.O., Takahashi T., Travassos L.R., Old L.J.

AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization.

Proc. Natl. Acad. Sci. U.S.A. 76:2898-2902(1979)

DOI=10.1007/978-1-4615-7228-2_39

Houghton A.N., Oettgen H.F., Old L.J.

Malignant melanoma. Current status of the search for melanoma-specific antigens.

(In book chapter) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston; USA (1981)

PubMed=7017212; DOI=10.1093/jnci/66.6.1003

Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.

HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.

J. Natl. Cancer Inst. 66:1003-1012(1981)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

PubMed=2041050; DOI=10.1093/jnci/83.11.757

Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=7999427; DOI=10.1016/0959-8049(94)90188-0

Marshall E.S., Matthews J.H.L., Shaw J.H.F., Nixon J., Tumewu P., Finlay G.J., Holdaway K.M., Baguley B.C.

Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays.

Eur. J. Cancer 30A:1370-1376(1994)

PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H

Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J., McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M., van Zijl P.L.

Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.

Eur. J. Cancer 31A:230-237(1995)

PubMed=7747814; PMCID=PMC1869278

Gruis N.A., Weaver-Feldhaus J.M., Liu Q.-Y., Frye C., Eeles R., Orlow I., Lacombe L., Ponce-Castaneda V., Lianes P., Latres E., Skolnick M.H., Cordon-Cardo C., Kamb A.

Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.

Am. J. Pathol. 146:1199-1206(1995)

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

PubMed=11016658

Girnita L., Girnita A., Brodin B., Xie Y.-T., Nilsson G., Dricu A., Lundeberg J., Wejde J., Bartolazzi A., Wiman K.G., Larsson O.

Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact.

Cancer Res. 60:5278-5283(2000)

PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209

Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J., Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.

Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma.

Cancer Res. 64:1157-1163(2004)

PubMed=15299072; DOI=10.1158/1535-7163.895.3.8

Qin J.-Z., Stennett L., Bacon P., Bodner B., Hendrix M.J.C., Seftor R.E.B., Seftor E.A., Margaryan N.V., Pollock P.M., Curtis A., Trent J.M., Bennett F., Miele L., Nickoloff B.J.

p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas.

Mol. Cancer Ther. 3:895-902(2004)

PubMed=15467732; DOI=10.1038/sj.onc.1208152

Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J., Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.

Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.

Oncogene 23:8796-8804(2004)

PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742

Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.

HLA class I and II genotype of the NCI-60 cell lines.

J. Transl. Med. 3:11.1-11.8(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Miroo T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152

Stark M.S., Hayward N.K.

Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.

Cancer Res. 67:2632-2642(2007)

PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x

Johansson P., Pavey S., Hayward N.K.

Confirmation of a BRAF mutation-associated gene expression signature in melanoma.

Pigment Cell Res. 20:216-221(2007)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356

Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

DNA fingerprinting of the NCI-60 cell line panel.

Mol. Cancer Ther. 8:713-724(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108

Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=21725359; DOI=10.1038/onc.2011.250; PMCID=PMC3267014

Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M., She Q.-B., Gallardo H.F., Liu C., Merghoub T., Hefter B.E., Dolgalev I., Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G., Wolchok J.D., Houghton A.N., Solit D.B.

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.

Oncogene 31:446-457(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665

Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189

Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Science 336:1040-1044(2012)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961

Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018

Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.

Global proteome analysis of the NCI-60 cell line panel.

Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206

Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Cancer Metab. 1:20.1-20.13(2013)

PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625; PMCID=PMC4005042

Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L., Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A., Chapman P.B., Yaeger R.D., Taylor B.S., Schultz N., Berger M.F., Rosen N., Solit D.B.

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Cancer Res. 74:2340-2350(2014)

PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652

Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877

Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=27600516; DOI=10.1007/s00262-016-1897-3; PMCID=PMC5509013

Gloger A., Ritz D., Fugmann T., Neri D.

Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.

Cancer Immunol. Immunother. 65:1377-1393(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121

Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Mob. DNA 7:20.1-20.11(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)"